Comparator supply is one of the most common causes of avoidable delay in clinical trial start up. The medicine itself is usually approved and commercially available, which leads teams to assume it can be bought like any other stock item. In practice a comparator carries the same regulatory weight as the investigational product it is being tested against, and it must be traceable back to the manufacturer with evidence that will survive a regulatory inspection years later.

This guide sets out how sponsors, clinical research organisations, and R&D procurement teams define, classify, source, and document comparator drugs across the UK, EU, US, and Indian regulatory routes.

What Is a Comparator Drug in a Clinical Trial?

A comparator drug is the medicine used as the reference treatment against which an investigational product is measured. It may be an active licensed medicine representing the current standard of care, or it may be a placebo.

The definitions matter because they determine your paperwork. Article 2(5) of Regulation (EU) No 536/2014 defines an investigational medicinal product as a medicinal product being tested or used as a reference, including as a placebo, in a clinical trial. The European Commission's questions and answers on the Regulation confirm directly that an authorised medicinal product used as a comparator in a trial is considered an IMP.

ICH E6(R3), the current Good Clinical Practice guideline, aligns with this. It defines an investigational product as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, and explicitly includes an authorised product when it is used or assembled differently from the approved form, used for an unapproved indication, or used to gain further information about an approved use. ICH adopted E6(R3) on 6 January 2025, and it came into force in the European Union on 23 July 2025.

The practical consequence is that a box of a well known branded medicine bought for a trial is not ordinary stock. It is regulated material, and it needs an IMP dossier, GMP assurance, QP release in the EU, trial specific labelling, and full accountability records.

Comparator or Auxiliary Medicinal Product? Why Classification Decides Your Paperwork

An auxiliary medicinal product (AxMP) is a medicine used in a trial that is not being tested and is not the reference. Rescue medication, background therapy, and premedication usually fall into this group. AxMPs require a simplified auxiliary dossier rather than a full IMP dossier, so getting the classification right early avoids substantial rework.

Classification is not always obvious, particularly in oncology combination protocols where the same molecule can be a test product in one arm and a comparator in another. European Commission guidance on auxiliary medicinal products addresses exactly these borderline cases and should be read alongside the protocol before any purchase order is raised.

Why Is Comparator Sourcing Harder Than Routine Procurement?

Comparators must match the protocol exactly on brand, strength, presentation, and often country of origin, while the originator has no obligation to supply a company running a competing trial. Four pressures make this difficult in practice.

• Supply volatility. Shortages remain a structural feature of pharmaceutical supply. ASHP and the University of Utah Drug Information Service recorded 89 new drug shortages in 2025, the lowest annual figure since 2006, but active ongoing shortages remained above 200, against a record high of 323 in early 2024. A comparator that is available when the protocol is written may be constrained by the time recruitment opens.
• No obligation to supply. An originator company is under no duty to sell its product to a sponsor testing a rival molecule against it. Direct supply is preferable where it can be secured, but it is frequently unavailable, which pushes teams into open market sourcing where provenance must be proved rather than assumed.
• Origin and presentation must match. The same brand can differ between markets in excipients, pack size, tablet debossing, or leaflet content. If the protocol or the regulatory submission specifies a market, sourcing from a different one can invalidate comparability.
• Blinding requirements. Over encapsulation or de-labelling changes the product, which brings further GMP and stability obligations and adds weeks to the timeline.

How Do You Source a Comparator Drug, Step by Step?

1. Define the comparator precisely in the protocol

Specify molecule, brand, marketing authorisation holder, strength, dosage form, pack size, and, where it matters, country of origin. Vague specification is the single most common cause of late stage sourcing failure, because a supplier can only source what has been defined. Agree at this point whether a market equivalent may be substituted and under what conditions.

2. Classify each product as IMP or AxMP

Do this before procurement, not after. The classification determines whether you need a full investigational medicinal product dossier or a simplified auxiliary dossier, how the product is registered in CTIS for EU trials, and what your supplier must provide.

3. Choose the sourcing route

Direct supply from the marketing authorisation holder gives the cleanest audit trail but is often refused or slow. Sourcing through a licensed specialist supplier gives access to multiple markets and faster turnaround, provided that supplier can evidence an unbroken chain back to the manufacturer. Whichever route you take, document why it was chosen.

4. Verify provenance and supply chain integrity

Establish that your supplier holds the relevant authorisation for its territory and operates to Good Distribution Practice, and that every batch can be traced to the manufacturer. In the EU, the Falsified Medicines Directive and Delegated Regulation (EU) 2016/161 require verification and decommissioning of the unique identifier at defined points. Guidance for clinical supply chains recommends sourcing directly from manufacturers, marketing authorisation holders, or their designated partners, verifying every pack before it reaches an investigator site, and excluding pharmacy returns from the clinical supply chain because of the additional risk they carry.

5. Secure the import and export approvals for each market

Requirements differ by jurisdiction and should be mapped country by country at the planning stage.

• European Union and United Kingdom. Every IMP batch must be certified by a Qualified Person before release for use in a trial, under Annex 13 of the EU GMP Guide. Where a comparator has been manufactured in a third country and full GMP assurance cannot be obtained, the QP must be satisfied that each production batch has been analysed and subjected to the checks and tests needed to confirm its quality. Building analytical testing time into the schedule is essential.
• India. Import of a new drug or investigational new drug for a clinical trial or bioequivalence study is applied for on Form CT-16 under the New Drugs and Clinical Trials Rules 2019, with the licence granted on Form CT-17. For a drug that is not a new drug, imported for examination, test, or analysis, the application is made on Form 12 under the Drugs and Cosmetics Rules 1945.
• United States. Comparator material supplied under an IND must satisfy the sponsor's obligations under 21 CFR Part 312, and domestic supply chain participants sit within the Drug Supply Chain Security Act framework.

6. Assemble the documentation pack

Documentation is what makes the comparator usable. Specify the full pack in the purchase agreement, not after delivery, and confirm the supplier can provide every item for every batch before you commit.

7. Plan cold chain and transport

For temperature sensitive comparators, agree the qualified shipping solution, the temperature range, the data logger specification, and the excursion management procedure in advance. Establish who assesses an excursion and who has authority to quarantine or release the affected consignment.

8. Plan quantities, expiry cover, and reconciliation

Order against recruitment forecasts with an overage allowance, and check remaining shelf life against expected trial duration. A comparator with twelve months of shelf life in a thirty month study will need at least one resupply, and that resupply may come from a different batch or market. Plan returns, accountability reconciliation, and destruction at the same time, because ICH E6(R3) applies full data governance expectations to IMP chain of custody records.

What Documents Should You Receive With a Comparator Shipment?

At minimum you need a batch specific Certificate of Analysis, a Certificate of Origin, proof of the supply chain back to the manufacturer, temperature records for the full transport leg, and the import or export licences for the route used. Regulatory dossier work and third country supply usually require more.

What Are the Most Common Comparator Sourcing Mistakes?

• Starting too late. Comparator sourcing is treated as a procurement task rather than a regulatory one, and begins after the protocol is locked instead of alongside it.
• Specifying loosely. A molecule name without brand, strength, presentation, or market leaves the supplier guessing and the sponsor exposed.
• Assuming documentation will follow. If the documentation pack is not written into the purchase agreement, batches arrive that cannot be released.
• Ignoring shelf life against study duration. Resupply planning that starts when stock runs low has already failed.
• Underestimating QP release time. Where third country GMP assurance is unavailable, batch analysis adds weeks that are rarely in the original plan.
• Accepting untraceable stock. Open market material without provenance back to the manufacturer is a serious inspection risk.

How Do You Evaluate a Comparator Drug Supplier?

Assess five things: licensing and certification status, ability to evidence provenance for every batch, documentation capability, multi market access with import and export experience, and validated cold chain handling. Ask for evidence rather than assurances, and test the answers against a live requirement before you commit to a study.

• Licences and certification. Confirm the relevant supply authorisation, WHO-GDP or GSDP certification, and quality management certification. Ask for current copies rather than logos on a website.
• Provenance capability. Ask how the supplier evidences the chain from manufacturer to your site, and what happens when a preferred source is unavailable.
• Documentation. Request a redacted example pack for a comparable shipment. Suppliers who routinely serve regulated trials will have one ready.
• Market reach. Multi country access matters when the protocol names a specific origin or a preferred market goes into shortage.
• Cold chain. Confirm qualified packaging, live monitoring, excursion procedures, and named responsibility for release decisions.
• Responsiveness. Comparator requests are often urgent. Quoting speed and the quality of the first technical response are reasonable proxies for how a supplier will behave under pressure.

If your programme also involves generic development rather than a trial, the terminology and sourcing constraints change. Our companion guide explains the difference between a comparator drug and a reference listed drug (RLD), and when each is required.

References

• Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, Article 2(5); European Commission, Clinical Trials Regulation (EU) No 536/2014, Questions and Answers, section 1.15. The rules governing medicinal products in the European Union, Volume 10.
• European Commission. Auxiliary Medicinal Products in Clinical Trials, guidance, March 2024.
• International Council for Harmonisation. ICH E6(R3) Guideline for Good Clinical Practice. Adopted 6 January 2025; applicable in the European Union from 23 July 2025. European Medicines Agency and US Food and Drug Administration.
• European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice, Annex 13: Investigational Medicinal Products and Annex 16: Certification by a Qualified Person and Batch Release.
• Directive 2011/62/EU (Falsified Medicines Directive) and Commission Delegated Regulation (EU) 2016/161 on safety features for the packaging of medicinal products for human use.
• The Role of the Falsified Medicines Directive and Delegated Regulation in the Supply Chain of Clinical Trials. Journal for Clinical Studies.
• Central Drugs Standard Control Organization (CDSCO). New Drugs and Clinical Trials Rules 2019, Forms CT-16 and CT-17; Drugs and Cosmetics Rules 1945, Form 12.
• US Food and Drug Administration. 21 CFR Part 312, Investigational New Drug Application; Drug Supply Chain Security Act (DSCSA).
• ASHP and University of Utah Drug Information Service. National Drug Shortage Statistics, 2025 and 2026 reporting.

Compiled from primary regulatory sources (EU Directives and Regulations, European Commission and EMA guidance, ICH guidelines, CDSCO rules and forms, and US Code of Federal Regulations) available as of July 2026. Regulatory requirements vary by jurisdiction and are subject to change; sponsors should verify the current position directly with the relevant competent authority.